GLP-1 Market
LLY $1143.12 ▲ +0.0% NVO $37.54 ▲ +0.6% PFE $27.41 ▼ -1.4% VKTX $29.28 ▼ -2.2% KLRA $10.84 ▲ +4.3% GPCR $27.59 ▼ -0.3% RHHBY $52.51 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Asedebart

Company
H. Lundbeck A/S
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 6, 2026

Find a Clinical Trial Near Me

See recruiting studies for Asedebart and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05669950

    A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

    Not yet reported, Not yet reported H. Lundbeck A/S 42 participants Est. completion 2027-12-31 17 sites Stand-alone
    Other conditions: Congenital Adrenal Hyperplasia
    View official trial listing →
  • Recruiting NCT NCT06471829

    A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

    Not yet reported H. Lundbeck A/S 18 participants Est. completion 2027-10-31 28 sites Stand-alone
    Other conditions: Cushing's Disease
    View official trial listing →
  • Not yet recruiting NCT NCT07859293

    An Extension Trial of Asedebart in Participants With Congenital Adrenal Hyperplasia

    Not yet reported H. Lundbeck A/S 45 participants Est. completion 2031-07-31 Stand-alone
    Other conditions: Adrenal Hyperplasia, Congenital
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Asedebart, Lu AG13909

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.